Lead Product(s) : Ifx-1
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InflaRx Gets CHMP Opinion for GOHIBIC® for SARS-CoV-2 ARDS Treatment
Details : Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody being evaluated for treating acute respiratory distress syndrome.
Product Name : Ifx-1
Product Type : Antibody
Upfront Cash : Inapplicable
November 15, 2024
Lead Product(s) : Ifx-1
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable